Venture Capital

Early trial data for ABX1100 reveals a novel approach to reducing muscle damage in Pompe disease, offering hope for less burdensome treatment.

Ex-NFL star Mark Clayton’s headphone brand, LIVV Audio, partners with The Uptown Agency to take on giants like Beats with its athlete-built active gear.

As Churchill Capital XI's shares and warrants begin separate trading, what does this mean for investors and the hunt for Michael Klein's next big deal?

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

Crave lands the exclusive Canadian rights to SATURDAY NIGHT LIVE UK, a bold move to battle streaming giants with a globally recognized comedy franchise.

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

Ex-Joint Chiefs Vice Chair Admiral Grady joins Domino Data Lab's board, signaling a major push to accelerate AI for U.S. national security missions.

Colombier Acquisition Corp. III, with a board of political and tech heavyweights, has a $299M war chest. Its hunt for a 'patriotic' target begins.

New grants from the American Psychological Foundation fund direct interventions for trans youth and trauma-affected families, moving psychology from theory to action.

Karma Automotive will use Factorial's advanced solid-state batteries in its Kaveya supercar, sparking a new chapter for American EV manufacturing and innovation.

New data reveals Orca-T cell therapy boosts survival and cuts complications in blood cancer, as the company prepares for a potential FDA approval this year.

A new initiative unites top scientists to study 'SuperAgers' and resilient brains, aiming to unlock the secrets of healthy aging and prevent Alzheimer's.

With a key hire from IBM Watson Health, health AI firm Briya is set to scale its federated data platform, aiming to solve healthcare's research bottleneck.

With backing from top VCs, Angitia Biopharmaceuticals is accelerating its novel treatments for osteoporosis and rare bone disorders. Here's why it matters.

Nullify lands $12.5M to deploy autonomous AI security engineers, aiming to solve the cyber talent gap by replacing manual work with merge-ready code.

Pluristyx and Solesis launch a 'three-in-one' kit with nearly 100% efficiency in iPSC transfection, tackling a major bottleneck in organoid research.

Everbright Digital hopes a 1-for-16 reverse stock split will save its Nasdaq listing, but the move raises questions about its metaverse-focused future.

A new contract gives Canadian municipalities streamlined access to robotic mowers, a high-tech solution for labor shortages and budget pressures.

A new study reveals Exicure's burixafor mobilizes stem cells in one hour, promising to streamline cancer treatment and unlock future gene therapies.

For its tenth straight Games, Technogym will equip Milano Cortina 2026 with AI-driven gear, cementing its legacy as the force behind athletic excellence.